VBLT - Vascular Biogenics Ltd.
| Previous Close | 1.3000 |
| Open | 1.2900 |
| Bid | 0.6100 x 1200 |
| Ask | 1.5000 x 4000 |
| Day's Range | 1.2800 - 1.3200 |
| 52 Week Range | 0.6000 - 1.9000 |
| Volume | 2,736 |
| Avg. Volume | 23,753 |
| Market Cap | 47.004M |
| Beta (3Y Monthly) | 1.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5040 |
| Earnings Date | Nov 18, 2019 - Nov 22, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.94 |
- Simply Wall St.
Easy Come, Easy Go: How Vascular Biogenics (NASDAQ:VBLT) Shareholders Got Unlucky And Saw 80% Of Their Cash Evaporate
Some stocks are best avoided. We really hate to see fellow investors lose their hard-earned money. For example, we...
- Zacks
Vascular Biogenics (VBLT) Reports Q2 Loss, Misses Revenue Estimates
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 0.00% and -44.80%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
VBL Therapeutics Announces Second Quarter 2019 Financial Results
TEL AVIV, Israel, Aug. 13, 2019 -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the second quarter ended June 30, 2019, and provided a corporate.
- ACCESSWIRE
Vascular Biogenics Ltd. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 13, 2019 / Vascular Biogenics Ltd. (NASDAQ: VBLT ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 13, 2019 at 8:30 ...
- Zacks
Vascular Biogenics (VBLT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
VBL Therapeutics to Report Second Quarter 2019 Financial Results on August 13
TEL AVIV, Israel, Aug. 05, 2019 -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of.
- Simply Wall St.
Do Insiders Own Shares In Vascular Biogenics Ltd. (NASDAQ:VBLT)?
If you want to know who really controls Vascular Biogenics Ltd. (NASDAQ:VBLT), then you'll have to look at the makeup...
- GlobeNewswire
VBL Therapeutics Announces Modiin Production Facility Received a GMP Compliance Certificate Following EU QP Audit
TEL AVIV, Israel, July 22, 2019 -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of.
- GlobeNewswire
VBL Therapeutics to Provide Additional Details on the New VB-111 Data Presented Earlier This Week at ASCO, in a Presentation at the 2019 BIO International Convention Today
VBL Therapeutics (Nasdaq: VBLT), announced that Dr. Dror Harats, CEO will deliver a company presentation today at the 2019 BIO International Convention in Philadelphia. The presentation will include a discussion on the recent VB-111 progress, including data presented earlier this week at the 2019 ASCO Annual Meeting. The presentation will be also available to the investor audience by webcast.
- GlobeNewswire
VBL Final Phase 1/2 Study Results Presented at ASCO Demonstrate VB-111 Dose Dependent Increase in Overall Survival and 58% CA-125 Response Rate in Platinum-Resistant Ovarian Cancer
VBL Therapeutics (Nasdaq: VBLT) today announced the presentation of the final results from a Phase 1/2 clinical trial of VB-111 in the treatment of patients with recurrent platinum resistant ovarian cancer on Saturday, June 1st at the 2019 American Society of Clinical Oncology (ASCO) annual meeting, in Chicago. 58% of evaluable patients treated with the therapeutic dose of VB-111 had a GCIG CA-125 response.
- GlobeNewswire
Radiographic Analysis of VB-111 Phase 2 and 3 Clinical Trials in Recurrent Glioblastoma Shows Survival Benefit Associated with Objective Responses and Distinct Signature of VB-111 Activity
VBL Therapeutics (VBLT), today announced that MRI data from VB-111 Phase 2 and Phase 3 studies in recurrent GBM (rGBM), presented yesterday at the 2019 American Society of Clinical Oncology (ASCO) annual meeting, showed a survival benefit associated with objective responses to the compound and a distinct signature of VB-111 activity. The data were presented by Dr. Benjamin M. Ellingson, Ph.D., from the UCLA Brain Tumor Imaging Laboratory (BTIL), Department of Radiological Science. The UCLA analysis compared data from VBL's Phase 2 study of VB-111, which met the primary endpoint of OS benefit with a median OS (mOS) of 414 days, to MRI data from the treatment arm in the GLOBE Phase 3 study, which had a mOS of 6.8 months, despite similar baseline tumor volume between patient cohorts.
- GlobeNewswire
VBL Therapeutics Announces Presentations at the 2019 ASCO Annual Meeting and the BIO International Convention
TEL AVIV, Israel, May 23, 2019 -- VBL Therapeutics (Nasdaq: VBLT), today announced the upcoming presentation of final results from the Phase 2 study of VB-111 in ovarian cancer.
- Thomson Reuters StreetEvents
Edited Transcript of VBLT earnings conference call or presentation 15-May-19 12:30pm GMT
Q1 2019 Vascular Biogenics Ltd Earnings Call
- Zacks
Vascular Biogenics (VBLT) Reports Q1 Loss, Misses Revenue Estimates
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -100.00% and -90.48%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
Vascular Biogenics: 1Q Earnings Snapshot
The Modi In, Israel-based company said it had a loss of 12 cents per share. The gene therapy biotech company posted revenue of $219,000 in the period. The company's shares closed at $1.24. A year ago, ...
- GlobeNewswire
VBL Therapeutics Announces First Quarter 2019 Financial Results
TEL AVIV, Israel, May 15, 2019 -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the first quarter ended March 31, 2019, and provided a corporate update..
- TheStreet.com
Vascular Biogen Expected to Lose 12 Cents a Share
The stock has fallen 21.15% since the company last reported earnings on Mar. 28. Quarterly estimates have fallen 3 cents a share in the past month. Vascular Biogen is currently trading at a price-to-forward-earnings ratio of -2.2 based on the 12-month estimates of 3 analysts surveyed by FactSet.
- Zacks
Will Vascular Biogenics (VBLT) Report Negative Earnings Next Week? What You Should Know
Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
VBL Therapeutics to Report First Quarter 2019 Financial Results on May 15
TEL AVIV, Israel, May 06, 2019 -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of.
- Simply Wall St.
Those Who Purchased Vascular Biogenics (NASDAQ:VBLT) Shares Three Years Ago Have A 54% Loss To Show For It
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! It is doubtless a positive to see that the Vascular Biogenics Ltd. (NASDAQ:VBLT) share price has gained some 60% in the la...
- Thomson Reuters StreetEvents
Edited Transcript of VBLT earnings conference call or presentation 28-Mar-19 12:30pm GMT
Q4 2018 Vascular Biogenics Ltd Earnings Call
- Zacks
Vascular Biogenics (VBLT) Reports Q4 Loss, Misses Revenue Estimates
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 41.18% and -53.00%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- Benzinga
The Daily Biotech Pulse: Blueprint Medicine Expedites Clinical Programs, Eyepoint Offering, Precision Biosciences IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 27) Baxter International Inc (NYSE: BAX ) Catalyst Pharmaceuticals ...
- GlobeNewswire
VBL Therapeutics Announces Year Ended December 31, 2018 Financial Results and Provides Corporate Update
Development of Phase 3 product candidate VB-111 continues in ovarian cancer toward interim analysis at year-end 2019 and expands through investigator-sponsored trials in rGBM.
- GlobeNewswire
VBL Therapeutics to Present at Upcoming Conferences in April
TEL AVIV, Israel, March 25, 2019 -- VBL Therapeutics (Nasdaq: VBLT), today announces that the Company will present data on its Phase 3 drug candidate VB-111, at the 2019.
